litlas
Log inCreate account

David L. Kendler

Active 1993–2025

86
Papers
18,801
Citations
67
h-index
84
i10-index

Citations

Citations per year for David L. Kendler1994: 2 citations1995: 2 citations1996: 3 citations1997: 1 citations1998: 14 citations1999: 16 citations2000: 24 citations2001: 38 citations2002: 40 citations2003: 48 citations2004: 42 citations2005: 53 citations2006: 88 citations2007: 62 citations2008: 97 citations2009: 71 citations2010: 127 citations2011: 119 citations2012: 137 citations2013: 104 citations2014: 106 citations2015: 116 citations2016: 154 citations2017: 138 citations2018: 191 citations2019: 543 citations2020: 674 citations2021: 553 citations2022: 450 citations2023: 315 citations2024: 525 citations2025: 275 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,332 citing papers, 21.3% of this breakdownUnited Kingdom: 480 citing papers, 7.7% of this breakdownChina: 389 citing papers, 6.2% of this breakdownCanada: 348 citing papers, 5.6% of this breakdownItaly: 343 citing papers, 5.5% of this breakdownAustralia: 265 citing papers, 4.3% of this breakdownGermany: 258 citing papers, 4.1% of this breakdownJapan: 223 citing papers, 3.6% of this breakdownSwitzerland: 221 citing papers, 3.5% of this breakdownBelgium: 214 citing papers, 3.4% of this breakdownFrance: 198 citing papers, 3.2% of this breakdownNetherlands: 177 citing papers, 2.8% of this breakdown
0%21.3%Other 28.8%

Institutions

Fields

  • Medicine82.1%
  • Biochemistry, Genetics and Molecular Biology12.3%
  • Engineering1.8%
  • Immunology and Microbiology0.6%
  • Health Professions0.5%
  • Dentistry0.5%
  • Other2.2%

Topics

  • Bone health and osteoporosis research19.1%
  • Bone health and treatments15.1%
  • Bone Metabolism and Diseases9.7%
  • Bone and Joint Diseases6.5%
  • Hip and Femur Fractures3.4%
  • Parathyroid Disorders and Treatments2.9%
  • Other43.3%

Coauthors

All papers

Open in search
  1. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

    Authors: Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi, Jacques P. Brown, Roland Chapurlat, Steven R. Cummings, E. J. Czerwiński, Astrid Fahrleitner‐Pammer, David L. Kendler, Kurt Lippuner, Jean‐Yves Reginster, Christian Roux, Jorge Malouf, Michelle N. Bradley, Nadia Daizadeh, Andrea Wang, Paula Dakin, Nicola Pannacciulli, David W. Dempster, Socrates E. Papapoulos - The Lancet Diabetes & Endocrinology 2017 cited by 961

  2. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

    Authors: Bente Langdahl, Cesar Libanati, Daria B. Crittenden, Michael A. Bolognese, Jacques P. Brown, Nadia Daizadeh, Eva Dokoupilová, Klaus Engelke, Joel S. Finkelstein, Harry K. Genant, Stefan Goemaere, Lars Hyldstrup, Esteban Jódar-Gimeno, Tony M. Keaveny, David L. Kendler, Péter Lakatos, Judy Maddox, Jorge Malouf, Fabio Massari, José Fernando Molina, María Rosa Ulla, Andreas Grauer - The Lancet 2017 cited by 467

  3. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

    Authors: David L. Kendler, Fernando Marín, Cristiano A. F. Zerbini, Luis Augusto Tavares Russo, Susan L. Greenspan, Vı́t Zikán, A. Bagur, Jorge Malouf-Sierra, Péter L. Lakatos, Astrid Fahrleitner‐Pammer, Éric Lespessailles, Salvatore Minisola, J.J. Body, Piet Geusens, R Möricke, Pedro López‐Romero - The Lancet 2017 cited by 581

  4. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

    Authors: Aliya Khan, Archie Morrison, David A. Hanley, Dieter Felsenberg, Laurie K. McCauley, Felice O’Ryan, Ian R. Reid, Salvatore L. Ruggiero, Akira Taguchi, Sotirios Tetradis, Nelson B. Watts, Maria Luisa Brandi, Edmund Peters, Teresa Guise, Richard Eastell, Angela M. Cheung, Suzanne N. Morin, Basel Masri, Cyrus Cooper, Sarah Morgan, Barbara Obermayer‐Pietsch, Bente Langdahl, Rana Al Dabagh, Kelly Davison, David L. Kendler, George K.B. Sándor, Robert G. Josse, Mohit Bhandari, Mohamed El Rabbany, Dominique D. Pierroz, Riad A. Sulimani, Deborah Saunders, Jacques P. Brown, Juliet Compston, on behalf of the International Task Force on Osteonecrosis of the Jaw - Journal of Bone and Mineral Research 2014 cited by 1,345

  5. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

    Authors: David L. Kendler, Felicia Cosman, Robert Stad, Serge Ferrari - Advances in Therapy 2021 cited by 212

  6. Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

    Authors: Henry G. Bone, Michael A. Bolognese, Chui Kin Yuen, David L. Kendler, Paul D. Miller, YuChing Yang, Luanda Grazette, Javier San Martín, John C. Gallagher - The Journal of Clinical Endocrinology & Metabolism 2011 cited by 611

  7. Romosozumab and antiresorptive treatment: the importance of treatment sequence

    Authors: Felicia Cosman, David L. Kendler, Bente Langdahl, Benjamin Z. Leder, E. Michael Lewiecki, Akimitsu Miyauchi, Maria Rojeski, Michele McDermott, Mary Oates, Cassandra E. Milmont, Cesar Libanati, Serge Ferrari - Osteoporosis International 2022 cited by 111

  8. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab

    Authors: David L. Kendler, Henry G. Bone, Francesco Massari, Evelien Gielen, Santiago Palacios, Judy Maddox, Chao Yan, Susan Yue, Rajani Dinavahi, Cesar Libanati, Andreas Grauer - Osteoporosis International 2019 cited by 122

  9. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

    Authors: David L. Kendler, Christian Roux, Claude Laurent Benhamou, Jacques P. Brown, Michael Lillestol, Suresh Siddhanti, H Man, Javier San Martín, Henry G. Bone - Journal of Bone and Mineral Research 2009 cited by 451

  10. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice

    Authors: Nicholas C. Harvey, Claus‐Christian Glüer, Neil Binkley, Eugène McCloskey, Maria Luisa Brandi, Cyrus Cooper, David L. Kendler, Olivier Lamy, Andrea Laslop, Bruno Muzzi Camargos, J.-Y. Reginster, René Rizzoli, J. A. Kanis - Bone 2015 cited by 473

  11. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

    Authors: Michael R. McClung, Steven T. Harris, Paul D. Miller, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, David L. Kendler, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2012 cited by 453

  12. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

    Authors: on behalf of the DAPS Investigators, Nick Freemantle, Sacha Satram‐Hoang, En‐Tzu Tang, Primal Kaur, David Macarios, Suresh Siddhanti, Jeff Borenstein, David L. Kendler - Osteoporosis International 2011 cited by 283

  13. Vertebral Fractures: Clinical Importance and Management

    Authors: David L. Kendler, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, S. T. Harris, Michael R. McClung, Paul D. Miller, John T. Schousboe, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2015 cited by 315

  14. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use

    Authors: Anthony B. Hodsman, Douglas C. Bauer, David W. Dempster, Larry Dian, David A. Hanley, Steven T. Harris, David L. Kendler, Michael R. McClung, Paul D. Miller, Wojciech P. Olszynski, Eric Orwoll, Chui Kin Yuen - Endocrine Reviews 2005 cited by 721

  15. Bone Mineral Density After Transitioning From Denosumab to Alendronate

    Authors: David L. Kendler, Arkadi Chines, Patricia Clark, Peter R. Ebeling, Michael R. McClung, Yumie Rhee, Shuang Huang, Robert Stad - The Journal of Clinical Endocrinology & Metabolism 2019 cited by 113

  16. Alendronate for the Treatment of Osteoporosis in Men

    Authors: Eric Orwoll, Mark P. Ettinger, Stuart Weiss, Paul D. Miller, David L. Kendler, John Graham, Silvano Adami, Kurt Weber, R Lorenc, Peter Pietschmann, Kristel Vandormael, Antonio Lombardi - New England Journal of Medicine 2000 cited by 977

  17. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease

    Authors: Aaron Broadwell, Arkadi Chines, Peter R. Ebeling, Edward Franek, Shuang Huang, Shawna Smith, David L. Kendler, Osvaldo Daniel Messina, Paul D. Miller - The Journal of Clinical Endocrinology & Metabolism 2020 cited by 88

  18. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial

    Authors: E. J. Czerwiński, José Cardona, Rafal Plebanski, Chris Recknor, Tamara Vokes, Kenneth G. Saag, Neil Binkley, E. Michael Lewiecki, Jonathan D. Adachi, Dorota Knychas, David L. Kendler, Eric Orwoll, Yinzhong Chen, Leny Pearman, Y Heather Li, Bruce Mitlak - Journal of Bone and Mineral Research 2020 cited by 43

  19. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis

    Authors: Adolfo Díez‐Pérez, Fernando Marín, Erik Fink Eriksen, David L. Kendler, John H. Krege, Miguel Delgado‐Rodríguez - Bone 2018 cited by 111

  20. Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors

    Authors: Gemma Marcucci, Giovanni Beltrami, A. Tamburini, Jean‐Jacques Body, C Confavreux, Peyman Hadji, Gerold Holzer, David L. Kendler, Nicola Napoli, Dominique D. Pierroz, R. Rizzoli, Maria Luisa Brandi - Annals of Oncology 2019 cited by 85

  21. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

    Authors: Henry G. Bone, Michael A. Bolognese, Chui Kin Yuen, David L. Kendler, Huei Wang, Yu Liu, Javier San Martín - The Journal of Clinical Endocrinology & Metabolism 2008 cited by 427

  22. Lasofoxifene in Postmenopausal Women with Osteoporosis

    Authors: Steven R. Cummings, Kristine E. Ensrud, Pierre D. Delmas, Andrea Z. LaCroix, Slobodan Vukičević, David M. Reid, Steven R. Goldstein, Usha Sriram, Andy Lee, John R. Thompson, Róisín Armstrong, David D. Thompson, Trevor J. Powles, José Zanchetta, David L. Kendler, Patrick Neven, Richard Eastell - New England Journal of Medicine 2010 cited by 383

  23. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions

    Authors: E. Michael Lewiecki, Catherine M. Gordon, Sanford Baim, Mary B. Leonard, Nicholas Bishop, Maria-Luisa Bianchi, Heidi J. Kalkwarf, Craig B. Langman, Horatio Plotkin, Frank Rauch, Babette S. Zemel, Neil Binkley, John P. Bilezikian, David L. Kendler, Didier Hans, Stuart Silverman - Bone 2008 cited by 577

  24. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ

    Authors: Aliya Khan, Archie Morrison, David L. Kendler, René Rizzoli, David A. Hanley, Dieter Felsenberg, Laurie K. McCauley, Felice O’Ryan, Ian R. Reid, Salvatore L. Ruggiero, Akira Taguchi, Sotirios Tetradis, Nelson B. Watts, Maria Luisa Brandi, Edmund Peters, Teresa Guise, Richard Eastell, Angela M. Cheung, Suzanne N. Morin, Basel Masri, Cyrus Cooper, Sarah L. Morgan, Barbara Obermayer‐Pietsch, Bente Langdahl, Rana Al Dabagh, Kelly Davison, George K.B. Sándor, Robert G. Josse, Mohit Bhandari, Mohamed El Rabbany, Dominique D. Pierroz, Riad A. Sulimani, Deborah Saunders, Jacques P. Brown, Juliet Compston - Journal of Clinical Densitometry 2016 cited by 263